ID   IHH-4
AC   CVCL_2960
SY   IHH4
DR   CLO; CLO_0037153
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03481111
DR   cancercelllines; CVCL_2960
DR   Cell_Model_Passport; SIDM00600
DR   Cosmic; 1995454
DR   Cosmic; 2054088
DR   Cosmic-CLP; 1240154
DR   DepMap; ACH-001528
DR   EGA; EGAS00001000978
DR   GDSC; 1240154
DR   GEO; GSM827172
DR   GEO; GSM1669931
DR   JCRB; JCRB1079
DR   JCRB; NIHS0270
DR   JCRB; NIHS0270.1
DR   JCRB; NIHS0271.1
DR   LINCS_LDP; LCL-1693
DR   PharmacoDB; IHH4_655_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_2960
DR   Wikidata; Q54897412
RX   PubMed=11686581;
RX   PubMed=20215515;
RX   PubMed=23833040;
RX   PubMed=27397505;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 42 hours (PubMed=11686581).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Trp592Ter (c.1776G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 14281; CRLF2; Simple; p.Trp255Ter (c.765G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Arg1312Ter (c.3934C>T); ClinVar=VCV000545969; Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp11Glu (c.33C>G); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.71%; Native American=0%; East Asian, North=73.08%; East Asian, South=21.44%; South Asian=0%; European, North=0.89%; European, South=2.88% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0270; true.
CC   Discontinued: JCRB; NIHS0270.1; true.
CC   Discontinued: JCRB; NIHS0271.1; true.
CC   Derived from site: Metastatic; Left cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; DepMap; JCRB; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 10,13
ST   D16S539: 9,11
ST   D18S51: 13,15
ST   D21S11: 30,31
ST   D3S1358: 16
ST   D5S818: 9,13
ST   D7S820: 9,10
ST   D8S1179: 11,15
ST   FGA: 23,24
ST   Penta D: 9
ST   Penta E: 10,12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 16,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7;
RA   Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I.,
RA   Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.;
RT   "Biological characteristics and chemosensitivity profile of four human
RT   anaplastic thyroid carcinoma cell lines.";
RL   Biomed. Pharmacother. 55:466-474(2001).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//